The healthcare sector, long seen as a steady but unexciting part of the market, has emerged as one of 2026’s strongest performers as investors disillusioned with returns from large AI projects moved capital into safer bets. MarketWatch reports that shares of drugmakers, health insurers and diagnostic laboratories have attracted significant inflows since June and repeatedly hit new highs.
What changed and why it matters
Investor reallocations followed growing skepticism about the returns on huge AI investments. That trend was reinforced by another wave of selling in technology stocks this week, partly driven by concerns that AI is already putting pressure on Alphabet — the parent company of Google — and its core search business. A co‑founder of DataTrek Research said many investors have lost patience with burning billions on a technology that so far resembles more of a scientific experiment than a proven commercial platform.
Analysts at RBC Capital Markets also confirmed the capital rotation, noting that AbbVie shares tend to do particularly well on days when technology stocks are sold off.
Results and concrete numbers
The rally is underpinned by solid fundamentals. AbbVie, Gilead Sciences, Eli Lilly and Johnson & Johnson are trading at or near historic highs. According to the report, those stocks have risen at least 29 percent this year; leading names such as Gilead and Merck are up roughly 41 percent since the start of the year.
This week, Gilead reported what it called its best quarter in a decade; Eli Lilly raised its revenue guidance for the third time this year; and Merck’s third‑quarter results substantially beat expectations. Companies in the sector also have promising R&D pipelines, and earlier fears about aggressive drug‑pricing moves under the Trump administration have largely subsided.
The industry has recovered from a downturn that began around 2022, during which many large drugmakers underwent restructurings, laid off thousands of employees and halted dozens of clinical programs amid the introduction of more stringent government price‑control initiatives.
Risks and outlook
Risks remain. For example, analysts are already debating when Gilead’s HIV business growth might peak due to intensifying competition. Still, RBC Capital Markets analysts judge that companies’ operational performance is currently strong, supporting current valuations.
Beyond pharma, health insurers and diagnostic labs have also performed strongly after a turbulent 2025. UnitedHealth shares are up 23.5 percent year‑to‑date, Humana about 61 percent, and Oscar Health has surged 112 percent. Labcorp shares have risen 42.9 percent and Quest Diagnostics 45.1 percent since the start of the year.
Conclusion
The 2026 market shift suggests investors are favoring sectors with steadier, more predictable growth profiles over high‑cost AI experiments with uncertain payoffs. Combined with robust quarterly results and easing regulatory concerns, these factors have propelled healthcare to a leading role in this year’s market performance.
An AI assistant contributed to the preparation of this article; the final content was edited and verified by our journalist.
